Anna Health Secures $9.26 Million for Innovative Autism Therapy

$9.26 Million for a Different Autism Model

SUDBURY, MASSACHUSETTS — Anna Health Inc., which CEO Aimun Malik says stands for the Allied Network for Neurodevelopmental Advancement, raised $9.26 million of a $9.41 million funding round in November 2024, according to public SEC filings reported by Behavioral Health Business. The round drew checks from venture capital firms Virtue (Austin), GreyMatter Capital (San Francisco, founded 2021 and focused on mental and brain health), re:Mind Capital, and Watershed Ventures. Malik described the company’s services to Autism Business News as “naturalistic, play-based, and child-led,” a clinical positioning that distinguishes Anna Health from the discrete-trial ABA model that has dominated the industry.

Anna Health was founded in 2023 and operates from 490 Boston Post Road in Sudbury, west of Boston. The company delivers Naturalistic Developmental Behavioral Interventions, commonly abbreviated NDBIs, which integrate developmental science principles with applied behavior analysis techniques. Rather than the structured, clinician-directed format of traditional discrete trial training, NDBIs are delivered in natural environments, use the child’s interests and motivations as the basis for learning opportunities, and emphasize the child’s active role in directing the therapeutic interaction. The peer-reviewed evidence base for NDBIs traces back to a 2015 consensus paper in the Journal of Autism and Developmental Disorders by Laura Schreibman and 12 collaborators, which established the umbrella term and the shared technical features.

Anna Health pairs its NDBI delivery with parent coaching through Project ImPACT, a structured program that trains caregivers to use NDBI techniques in everyday interactions with their children. The parent-coaching component extends the therapeutic activity beyond clinical sessions and into the home, where children spend most of their time. The company also provides insurance navigation, helping families pursue coverage for services that some payers have historically been reluctant to authorize at the same rates as discrete-trial ABA.

We plan to add neuropsychological evaluations, speech-language pathology, occupational therapy and physical therapy, all offered in coordination and in the context of NDBI, and in a way that aligns with our neuroaffirming values. — Aimun Malik, CEO, Anna Health, in remarks to Behavioral Health Business / Autism Business News (November 2024)

How NDBIs Differ From Discrete Trial ABA

The traditional ABA model that has dominated the autism therapy industry since the 1990s is built on discrete trial training. The format is structured, repetitive practice of specific skills in a controlled environment, with clear antecedents, responses, and consequences. The model has a substantial evidence base and has produced measurable improvements in language, social skills, and adaptive behavior across decades of research. The same model has also drawn criticism for being overly rigid, insufficiently attentive to the child’s natural motivations, and focused on behavioral compliance rather than developmental growth.

NDBIs were introduced as a formal category in a 2015 paper led by Laura Schreibman of UC San Diego. The Schreibman framework gathered several similar interventions under one umbrella, including Pivotal Response Treatment, the Early Start Denver Model, Enhanced Milieu Teaching, JASPER (Joint Attention, Symbolic Play, Engagement and Regulation), Reciprocal Imitation Training, and Project ImPACT. These approaches share a set of features. They are delivered in natural settings rather than in clinic chairs at a table. They share control between the child and the therapist, with the therapist following the child’s lead. They use natural reinforcers tied to the child’s actual interests, rather than arbitrary rewards. And they target a developmental sequence of skills, with joint attention and reciprocal social interaction as building blocks for language and play.

For the ABA industry, the rise of NDBI-focused providers raises concrete strategic questions. If payers move toward recognizing NDBI delivery under existing ABA CPT codes, or if they begin to require demonstrated NDBI competency for higher-tier rates, traditional ABA providers will need to retrain BCBAs and supervisors who were taught primarily within a discrete-trial paradigm. The clinical workforce implication is non-trivial. A BCBA whose practicum hours, supervision, and client experience were all in discrete trial training cannot pivot to NDBI delivery on a one-week course. The transition requires structured supervision, observation of NDBI fidelity, and time.

The VC Wave Around Autism Care

Anna Health’s round is part of a broader surge of venture capital entering autism-focused startups across 2024 and 2025. The four most-cited deals of the period, by disclosure date, total just over $112 million in committed capital. In January 2024, San Francisco-based Forta closed a $55 million Series A led by Insight Partners, with participation from Exor Ventures, Alumni Ventures, Trailmix Ventures, Tectonic Ventures, Gaingels, Asymmetric Capital Partners, Launch Bay Capital, The House Fund, and a roster of consumer-tech founders. Forta delivers virtual ABA through trained parents in 47 states as of August 2025, and a 2024 peer-reviewed Cureus study reported a 76 percent goal-achievement improvement among 25 pediatric patients on the Forta model.

Anna Health’s $9.26 million followed in November 2024. In January 2025, Weston, Florida-based Prosper Health raised $16.2 million for a telehealth platform serving autistic and neurodivergent adults, with investors including Maverick Ventures, BoxGroup, Haystack Fund, Kindred Ventures, and Spice Capital. In February 2025, Denver-based Frontera Health launched with a $32 million seed round co-led by Lux Capital and Lightspeed Venture Partners, with Bison Ventures, Menlo Ventures, and Inspired Capital participating. Frontera CEO Amol Deshpande, the parent of an autistic child, is building AI tools for diagnosis and assessment that aim to compress BCBA assessment-report time from days to two or three hours.

What unites the four companies is a shared bet against the assumption that center-based, clinician-directed, fee-for-service ABA is the only viable shape for autism care. Each tests a different hypothesis. Forta wagers on virtual delivery and trained parents. Frontera wagers on AI-assisted clinical workflows. Prosper wagers on adult-focused, neuroaffirming telehealth. Anna Health wagers on the NDBI clinical model and integrated developmental services. None of these companies is large enough to threaten established PE-backed ABA platforms in the near term. If any of the four models proves clinically superior, more cost-effective, or more attractive to payers, the competitive dynamics could shift meaningfully within five to seven years. PE-backed platforms watching this wave have a familiar option: acquire VC-funded startups once their models are validated, the same pattern that runs through most healthcare-services M&A.

The clinician-directed discrete trial does not disappear in the Anna Health model. It moves into the background. Play-based, child-led work in natural settings becomes the primary therapeutic surface, and the discrete trial becomes one tool among many.

What the Funding Does Not Promise

A $9.26 million seed round buys roughly 18 to 24 months of operating runway for an early-stage autism services startup that has to build clinical infrastructure, hire BCBAs, navigate payer contracts in Massachusetts, and demonstrate outcomes. It does not, by itself, prove that NDBI delivery is reimbursable at parity with discrete trial ABA. It does not prove that Anna Health’s neuroaffirming positioning will translate into measurable clinical outcomes that hold up in peer-reviewed research. It does not establish that the planned multi-disciplinary expansion (neuropsychological evaluations, speech, OT, PT) will integrate cleanly with NDBI delivery rather than reproducing the siloed-specialty experience families already encounter elsewhere.

It also does not, by itself, change the BACB framework. Board Certified Behavior Analysts are credentialed under standards that center applied behavior analysis as the discipline. NDBI is delivered by BCBAs and other clinicians, but the certification, the supervision requirements, and the ethics code remain ABA. A startup organizing its identity around NDBI and neuroaffirming language operates inside the same regulatory and certification structure as a traditional ABA provider. The branding is different. The compliance surface is identical.

What to Watch Through 2026 and 2027

Several concrete inflection points will determine whether Anna Health’s round looks prescient or premature. First, payer recognition. If a major Medicaid plan or commercial payer publishes specific reimbursement guidance for NDBI delivery within the existing ABA CPT structure, NDBI-focused providers gain a clearer revenue path. Massachusetts, Anna Health’s home market, became the first state in 2024 to mandate ABA provider accreditation for MassHealth billing by the start of 2027, which raises the bar for any new provider in the state and could disproportionately favor providers with disciplined clinical operations.

Second, the next funding round. A typical seed-to-Series A path for healthcare services startups is 18 to 24 months. That puts Anna Health in window for a Series A announcement somewhere between mid-2026 and late 2026, assuming the company hits clinical and growth milestones. The size and lead investor of any Series A will signal how the broader VC market is reading the NDBI thesis after a year of clinic operations.

Third, the broader NDBI evidence base. Multiple meta-analyses published since 2023 have examined NDBI outcomes against traditional ABA. A 2025 systematic review and network meta-analysis in a peer-reviewed journal compared PRT, ESDM, JASPER, and other NDBIs on language and social-communication outcomes. As more head-to-head studies emerge, payers, regulators, and providers will have firmer ground for clinical and reimbursement decisions. If the evidence skews strongly in NDBI’s favor, the wave of VC-funded NDBI-first startups looks like an early call rather than a fashionable one. If the evidence remains mixed, Anna Health and its peers will need to compete on operational execution as much as on clinical philosophy.

AT A GLANCE

SOURCES & REFERENCES